
|Articles|August 1, 2003
Transscleral drug delivery system under development
Fort Lauderdale, FL-Efforts to develop an episcleral anecortave acetate transscleral drug delivery system (AA-TSDDD), targeted for patients with age-related macular degeneration (AMD), are progressing initially in the rhesus monkey as preliminary devices are being redesigned to decrease postoperative problems, said Timothy W. Olsen, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
PRIMA retinal implant restores vision in patients with advanced GA
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































